RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of gamma-secretase/Notch signalling
pathway inhibitor RO4929097 (RO4929097) when given together with temozolomide and radiation
therapy in treating patients with newly diagnosed malignant glioma. Enzyme inhibitors, such
as gamma-secretase/Notch signalling pathway inhibitor RO4929097, may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy,
such as temozolomide, work in different ways to stop the growth of tumor cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading.
Radiation therapy uses high-energy x-rays to kill tumor cells. Giving gamma-secretase/Notch
signalling pathway inhibitor RO4929097 together with temozolomide and radiation therapy may
kill more tumor cells.